Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of diseases, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Company profile
Ticker
CDAKQ
Exchange
Website
CEO
Douglas Williams
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Codiak Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Codiak Securities Corporation ...
CDAKQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
2 May 23
NT 10-K
Notice of late annual filing
28 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Mar 23
8-K
Bankruptcy or Receivership
27 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Codiak BioSciences Reports Third Quarter 2022 Financial Results and Third Quarter 2022 and Recent Highlights
3 Nov 22
8-K
Codiak Announces Proposed Public Offering of Common Stock and Warrants
13 Sep 22
424B5
Prospectus supplement for primary offering
13 Sep 22
424B5
Prospectus supplement for primary offering
12 Sep 22
8-K
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring
30 Aug 22
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
FMR LLC
10 Apr 23
4
Yalonda Howze
30 Mar 23
4
Sriram Sathyanarayanan
30 Mar 23
4
Konstantin Konstantinov
30 Mar 23
4
Linda Bain
30 Mar 23
4
Nicole Barna
30 Mar 23
4
DOUGLAS E WILLIAMS
30 Mar 23
SC 13G/A
Laurion Capital Management LP
3 Mar 23
4
Linda Bain
21 Feb 23
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 55.93 mm | 55.93 mm | 55.93 mm | 55.93 mm | 55.93 mm | 55.93 mm |
Cash burn (monthly) | (no burn) | 3.90 mm | 7.13 mm | 4.44 mm | 3.37 mm | 5.59 mm |
Cash used (since last report) | n/a | 92.99 mm | 169.97 mm | 105.86 mm | 80.31 mm | 133.22 mm |
Cash remaining | n/a | -37.06 mm | -114.04 mm | -49.93 mm | -24.38 mm | -77.29 mm |
Runway (months of cash) | n/a | -9.5 | -16.0 | -11.2 | -7.2 | -13.8 |
Institutional ownership, Q1 2023
56.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 1 |
Closed positions | 16 |
Increased positions | 6 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 1.26 bn |
Total shares | 20.92 mm |
Total puts | 300.00 |
Total calls | 700.00 |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund VIII | 8.85 mm | $9.83 mm |
Flagship Ventures Fund V | 3.99 mm | $0.00 |
Flagship Pioneering | 3.54 mm | $617.84 mm |
Laurion Capital Management | 2.01 mm | $351.32 mm |
University Of Texas/texas Am Investment Managment | 847.11 k | $148.00 k |
Vanguard | 580.77 k | $101.34 mm |
FMR | 448.54 k | $78.27 mm |
Ensign Peak Advisors | 252.78 k | $44.11 mm |
Forefront Analytics | 110.21 k | $19.23 mm |
Parametrica Management | 65.10 k | $11.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Mar 23 | Yalonda Howze | Common Stock | Sell | Dispose S | No | No | 0.1955 | 1,628 | 318.27 | 7,458 |
29 Mar 23 | Nicole Barna | Common Stock | Sell | Dispose S | No | No | 0.166 | 1,932 | 320.71 | 4,849.257 |
29 Mar 23 | Nicole Barna | Common Stock | Sell | Dispose S | No | No | 0.1651 | 5,373 | 887.08 | 6,781.257 |
29 Mar 23 | Sriram Sathyanarayanan | Common Stock | Sell | Dispose S | No | No | 0.1652 | 11,762 | 1.94 k | 0 |
28 Mar 23 | Williams Douglas E | Common Stock | Sell | Dispose S | No | No | 0.18 | 41,667 | 7.50 k | 7,655 |
28 Mar 23 | Konstantin Konstantinov | Common Stock | Sell | Dispose S | No | No | 0.2 | 1,932 | 386.40 | 0 |
28 Mar 23 | Konstantin Konstantinov | Common Stock | Sell | Dispose S | No | No | 0.2001 | 7,432 | 1.49 k | 1,932 |